悦康药业：子公司注射液获FDA临床试验批准

Core Viewpoint - YKYY13 injection, developed by YKYY13 and Hangzhou Tianlong Pharmaceutical, has received FDA approval for clinical trials to treat chronic hepatitis B virus infection, marking a significant milestone in its development [1] Company Summary - YKYY13 injection is a double-stranded siRNA drug aimed at achieving functional cure for hepatitis B by inhibiting HBV replication and pathogen protein production through RNA interference [1] - Preclinical studies have demonstrated significant HBV suppression activity in vitro and in vivo, along with good safety and tolerability in animal trials [1] Industry Summary - The FDA's approval signifies a phase of success in the drug's development, although the company cautions investors about the inherent uncertainties in drug development [1]